AccuraGen Nabs $40 Million in Series B Financing
NEW YORK (GenomeWeb) – Liquid biopsy startup AccuraGen said today that it has raised $40 million in a Series B financing round to support development and commercialization of its liquid biopsy technology, dubbed Firefly.
Junson Capital, Decheng Capital, Temasek investments, DT Capital, Stanford-StartX Fund, and Nan Fung Capital, along with Series A investors, participated in the round.
In addition, the company said that it had appointed Dan Zabrowski, head of sequencing and tissue diagnostics at Roche, and Junson Capital CEO Kevin Liu to its board.
Junson Capital, Decheng Capital, Temasek investments, DT Capital, Stanford-StartX Fund, and Nan Fung Capital, along with Series A investors, participated in the round.
In addition, the company said that it had appointed Dan Zabrowski, head of sequencing and tissue diagnostics at Roche, and Junson Capital CEO Kevin Liu to its board.